Projects per year
Personal profile
Biography
Dr Azad is an early-career medical oncologist and translational researcher with a special interest in genitourinary malignancies.
After completing his medical oncology training and a PhD in cell biology in Melbourne, Dr Azad moved to the British Columbia (BC) Cancer Agency and Vancouver Prostate Centre, Canada for a 2-year fellowship under the supervision of Professor Kim Chi, an internationally renowned prostate cancer researcher.
At BC Cancer Agency, Dr Azad played a major role in the development of five investigator-initiated clinical trials, was actively involved in outcomes research, and led pioneering studies centred on genomic profiling of circulating cell-free DNA in advanced prostate cancer patients developing resistance to next-generation hormonal agents. The significance of Dr Azad's work with cell-free DNA was recognized by four highly prestigious Merit Awards from the American Society of Clinical Oncology and first author publications in Clinical Cancer Research and JAMA Oncology.
Dr Azad has a strong academic record including 64 publications, a patent, 11 oral presentations at national and international meetings, Poster Highlights Sessions at the 2014 and 2015 ASCO Annual Meeting, 22 competitive prizes and awards and over $4.5M in competitive funding.
In November 2015, Dr Azad commenced appointments at Monash University and Monash Health, where he is leading a clinical and translational prostate cancer research program. His ongoing research centres on circulating biomarker analysis in advanced prostate cancer patients (supported by an NHMRC Project Grant) and the predictive utility of non-coding RNA for BET inhibition in prostate cancer (supported by a Victorian Cancer Agency Translational Research Project Grant). He is also actively involved in clinical trials and notably is the lead Australian investigator for two clinical trials in advanced prostate cancer patients.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Projects
-
New combination therapies for castration-resistant prostate cancer
Lawrence, M., Risbridger, G., Azad, A. & Taylor, R.
15/02/19 → 14/02/23
Project: Research
-
A novel strategy for targeting castrate-resistant prostate cancer
Risbridger, G., Tilley, W. D., Furic, L., Sandhu, S. K., Azad, A., Selth, L. & Lawrence, M.
National Health and Medical Research Council (NHMRC) (Australia)
1/01/18 → 31/12/21
Project: Research
-
Novel targeting of therapy-resistant prostate cancer cells.
Taylor, R., Risbridger, G., Azad, A. & Nim, H.
1/01/18 → 31/12/20
Project: Research
-
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
To, S. Q. G., Azad, A., Shortt, J., Wei, A., Shackleton, M. & Kenealy, M.
1/12/17 → 1/12/20
Project: Research
Research output
-
Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic
Loh, Z., Hawkes, E. A., Chionh, F., Azad, A. & Chong, G., Feb 2021, In : Clinical Lymphoma, Myeloma and Leukemia. 21, 2, p. e179-e184 6 p.Research output: Contribution to journal › Article › Research › peer-review
-
Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay
Fettke, H., Steen, J. A., Kwan, E. M., Bukczynska, P., Keerthikumar, S., Goode, D., Docanto, M., Ng, N., Martelotto, L., Hauser, C., Southey, M. C., Azad, A. A. & Nguyen-Dumont, T., Aug 2020, In : BioTechniques. 69, 2, p. 133-140 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
Kwan, E. M. & Azad, A. A., 1 Jul 2020, In : Current Opinion in Urology. 30, 4, p. 617-619 3 p.Research output: Contribution to journal › Article › Other › peer-review
Open Access1 Citation (Scopus) -
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Kohli, M., Tan, W., Zheng, T., Wang, A., Montesinos, C., Wong, C., Du, P., Jia, S., Yadav, S., Horvath, L. G., Mahon, K. L., Kwan, E. M., Fettke, H., Yu, J. & Azad, A. A., Apr 2020, In : EBioMedicine. 54, 11 p., 102728.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile3 Citations (Scopus) -
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Dhiantravan, N., Violet, J., Eapen, R., Alghazo, O., Scalzo, M., Jackson, P., Keam, S. P., Mitchell, C., Neeson, P. J., Sandhu, S., Williams, S. G., Moon, D., Lawrentschuk, N., Azad, A., Hofman, M. S. & Murphy, D. G., 7 Nov 2020, (Accepted/In press) In : European Urology Focus. 4 p.Research output: Contribution to journal › Article › Other › peer-review